Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01714752
Other study ID # 2012-02
Secondary ID
Status Completed
Phase N/A
First received October 19, 2012
Last updated September 27, 2013
Start date December 2012
Est. completion date September 2013

Study information

Verified date September 2013
Source French Cardiology Society
Contact n/a
Is FDA regulated No
Health authority France: Agence Nationale de Sécurité des Médicaments
Study type Interventional

Clinical Trial Summary

Heart failure with preserved ejection fraction (HFPEF) is common and is a real public health issue. Diagnosis, especially when there are no congestive signs, is difficult. It has been shown that many patients with suspected HFPEF had left ventricular (LV) filling pressures elevated only at exercise (normal at rest).

Using stress echocardiography and taking into account left atrial (LA) remodeling at rest as a "memory" of chronic elevation of filling pressures. We believe that it is possible to improve the noninvasive diagnosis of exercise elevation of the LV end-diastolic pressure (LVEDP).


Description:

Purpose Heart failure with preserved ejection fraction (HFPEF) is common and is a real public health issue. Diagnosis, especially when there are no congestive signs, is difficult. It has been shown that many patients with suspected HFPEF had left ventricular (LV) filling pressures elevated only at exercise (normal at rest).

Hypothesis Using stress echocardiography and taking into account left atrial (LA) remodeling at rest as a "memory" of chronic elevation of filling pressures. We believe that it is possible to improve the noninvasive diagnosis of exercise elevation of the LV end-diastolic pressure (LVEDP).

Methods Prospective, monocentric and comparative study: catheterization versus echocardiography.

60 patients referred for coronary angiography will be recruited consecutively during their hospitalization.

Patients should perform a low intensity and short duration exercise, in both catheterization and echo labs (pedaling 3 minutes at 25Watts then, 3 minutes at 50W) The LVEDP will be measured invasively with a pigtail, at rest and at both levels of exercise.

Echocardiography will be performed within 24 hours after catheterization, after a full examination at rest, an identical exercise (same intensity, same duration, same position of the patient) than made in catheterization lab will be done. Following parameters will be recorded at both stress levels: trans mitral flow, mitral annular pulsed tissue Doppler imaging (both lateral and septal) and tricuspid regurgitation flow.

The doctor who will perform the echocardiographic acquisitions will not be informed of the results of catheterization. The acquisitions will be analyzed in a second time still blinded to the catheterization data.

The following echocardiographic parameters will be collected and compared to the invasive measurement of LVEDP:

- Ratio between pulsed Doppler peak E velocity and peak Ea velocity obtained with tissue Doppler imaging (E/Ea ratio) at rest and exercise,

- maximal LA volume indexed to body area

- (maximal LA volume) to (maximal LV volume) ratio.

- LA distensibility defined by: (maximal LA volume - minimal LA volume) / (minimal LA volume)

- LA Global longitudinal strain Finally, it will be investigated whether the combined use of E/Ea ratio at exercise with LA remodeling indices (of morphology and/or function) improves the performance characteristics of diagnostic test, compared to a separate use of these parameters.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date September 2013
Est. primary completion date September 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients hospitalized for coronary angiography

- Sinus Rhythm

- Left ventricular Ejection Fraction > 50%

Exclusion Criteria:

- Age < 18years

- Hypertrophic Cardiomyopathy

- Cardiac transplantation

- Mitral stenosis

- Mitral insufficiency >2/4

- Severe calcification of mitral annulus

- Mitral prothesis or mitral repair

- aortic prothesis

- Severe aortic stenosis

- Atrial fibrillation

- Acute coronary syndrom < 3 months

- Left ventricular thrombus

- Severe renal Failure

- failure of radial way for coronary angiography

- coronary lesion indicating an angioplasty

- impossibility to perform an exercise

- refusal or inability to sign informed consent

- no French medical insurance

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms

  • Heart Failure With Preserved Ejection Fraction (HFPEF)
  • Left Ventricular End Diastolic Pressure (LVEDP)

Intervention

Procedure:
measure of left ventricular and diastolic pressure at exercise


Locations

Country Name City State
France Pitié Salpêtrière Hospital - Cardiology Department Paris

Sponsors (2)

Lead Sponsor Collaborator
French Cardiology Society French Federation of Cardiology

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary E/Ea ratio E/Ea ratio as a non-invasive index of Left Ventricular and diastolic pressure (LVEDP) at exercise Day 1 No
Secondary left atrial (LA) morphology To evaluate left atrial (LA) morphology at rest (maximal LA volume indexed to body area, maximal LA volume to maximal LV volume ratio) as an index of Left Ventricular end diastolic pressure (LVEDP) at exercise. Day 1 No
Secondary LA function at rest To evaluate LA function at rest (distensibility, global longitudinal strain) as an index of Left Ventricular end diastolic pressure (LVEDP) at exercise. Day 1 No
Secondary E/Ea ratio at exercise with LA remodeling indices at rest To investigate whether the combined use of E/Ea ratio at exercise with LA remodeling indices at rest (of morphology and/or function) improves the performance characteristics of diagnostic test compared to a separate use of these parameters. Day 1 No
See also
  Status Clinical Trial Phase
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2
Recruiting NCT05441839 - UK Heart Failure With Preserved Ejection Fraction
Completed NCT01989299 - Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction
Terminated NCT03909295 - An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan. Phase 3
Completed NCT04327024 - Study of Verinurad in Heart Failure With Preserved Ejection Fraction Phase 2
Active, not recruiting NCT05136820 - Flow Regulation by Opening the SepTum in Patients With Heart Failure; a Prospective, Randomized, Sham-controlled, Double-blind, Global Multicenter Study N/A
Completed NCT03988634 - Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF) Phase 3
Recruiting NCT03876223 - Women's Ischemia Syndrome Evaluation (WISE) Pre-HFpEF
Completed NCT04232345 - A Study to Assess the Effect AZD4831 in Japanese and Chinese Healthy Volunteers Phase 1
Recruiting NCT05792059 - DevElopMent of Clinical PATHwaYs to the Diagnosis of Heart Failure With Preserved Ejection Fraction
Completed NCT03843060 - A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers Phase 1
Recruiting NCT06036186 - Study for the Treatment of Heart Failure With Preserved Ejection Fraction Associated With High Blood Pressure Using Right Atrial Pacing Controlled by the PressurePaceTM System N/A
Recruiting NCT05383287 - Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)
Completed NCT03877224 - DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction Phase 3
Active, not recruiting NCT04847557 - A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial Phase 3
Recruiting NCT04822649 - Exercise Capacity According to Coronary Microvascular Dysfunction and Body Composition N/A